Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group-Reference-Cited by-同舟云学术

Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group

Published:2021-09 Issue:3 Volume:20 Page:245-255
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Dunn Catherine^ORCID,Hong Wei^ORCID,Gibbs Peter,Ackland Stephen,Sjoquist Katrin^ORCID,Tebbutt Niall C.,Price Timothy,Burge Matthew

Funder

Servier Institute

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference60 articles.

1. International Agency for Research on Cancer. GLOBOCAN: Estimated cancer incidence, mortality and prevalence worldwide in 2018. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed: December 1, 2020.

2. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer;Cremolini;J Clin Oncol,2020

3. National Comprehensive Cancer Network. Colon Cancer. Version 4. 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed: November 23, 2020.

4. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial;Bennouna;Lancet Oncol,2013

5. Cost implications of new treatments for advanced colorectal cancer;Wong;Cancer,2009

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measuring Quality in the Care of Metastatic Colorectal Cancer Utilising Available Registry Data: A Modified Delphi Study;2024

2. Low intensity treatment in metastatic colorectal cancer;The Lancet Gastroenterology & Hepatology;2023-02

3. Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers;World Journal of Gastrointestinal Oncology;2022-01-15